key: cord-0810666-yqyahtpw authors: Kato, Yuri; Nishiyama, Kazuhiro; Nishimura, Akiyuki; Noda, Takamasa; Okabe, Kaori; Kusakabe, Takahiro; Kanda, Yasunari; Nishida, Motohiro title: Drug repurposing for the treatment of COVID-19 date: 2022-04-25 journal: J Pharmacol Sci DOI: 10.1016/j.jphs.2022.04.007 sha: ed1f1cc499777b4dfe77cf7d9a5519c92a0621a7 doc_id: 810666 cord_uid: yqyahtpw Coronavirus disease 2019 (COVID-19) remains prevalent worldwide since its onset was confirmed in Wuhan, China in 2019. Vaccines against the causative virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have shown a preventive effect against the onset and severity of COVID-19, and social and economic activities are gradually recovering. However, the presence of vaccine-resistant variants has been reported, and the development of therapeutic agents for patients with severe COVID-19 and related sequelae remains urgent. Drug repurposing, also called drug repositioning or eco-pharma, is the strategy of using previously approved and safe drugs for a therapeutic indication that is different from their original indication. The risk of severe COVID-19 and mortality increases with advancing age, cardiovascular disease, hypertension, diabetes, and cancer. We have reported three protein–protein interactions that are related to heart failure, and recently identified that one mechanism increases the risk of SARS-CoV-2 infection in mammalian cells. This review outlines the global efforts and outcomes of drug repurposing research for the treatment of severe COVID-19. It also discusses our recent finding of a new protein–protein interaction that is common to COVID-19 aggravation and heart failure. In late 2019, COVID-19 rapidly became prevalent throughout the world 1, 2 . SARS-CoV-2 can directly infect cardiomyocytes to impair cardiac function [26] [27] [28] . In 83 addition, the ACE2 expression level was found to be increased in the lungs of infected 84 patients, and genome-wide analyses have shown that ACE2 expression is low in 85 non-infected people 29, 30 . These findings suggest that the ACE2 expression level reflects 86 one's susceptibility to SARS-CoV-2 infection. Viral RNA has been detected in 87 cardiomyocytes taken from heart specimens of COVID-19 patients, revealing that 88 SARS-CoV-2 can infect heart tissue 31 . 89 Drug repurposing, also known as drug repositioning or eco-pharma 32 , is an (Table 1) . However, many patients still 96 suffer from COVID-19 aggravation and sequelae; thus, there is a need for the rapid 97 repurposing of drugs with mechanisms of action other than those currently approved for 98 treating COVID-19. In this review, we discuss our efforts related to drug repurposing, 99 focusing on the treatment of heart failure and their relation to finding new treatments for 100 severe COVID-19. to their mechanism of action: inhibitors of RNA-dependent RNA polymerase; inhibitors of serine protease (TMPRSS2); inhibitors of the main cysteine protease 3CL pro ; and 109 inhibitors of inflammation and cytokine storm (Figure 1) Ritonavir is thought to boost the lopinavir concentration by inhibiting CYP3A4 45 . The Other anti-inflammatory drugs target cytokine storm after SARS-CoV-2 infection. 133 134 3. Cardiac dysfunction as a major symptom of COVID-19 severity and sequelae 135 Coronaviruses are known for their impact on the respiratory tract, but 136 SARS-CoV-2 can also infect heart tissue 25-28 , which leads to a spectrum of cardiac 137 manifestations, including inflammation (myocarditis), arrhythmias, heart attack-like 138 symptoms, and heart failure 48 . The tropism of organs has been studied from autopsy 139 specimens. Sequencing data revealed that SARS-CoV-2 genomic RNA was highest in 140 the lungs, but the heart, kidney, and liver also showed substantial amounts 49 . Greater 165 We have reported three pathology-dependent protein-protein interactions 166 (PPIs) that participate in the progression of cardiovascular remodeling in mice ( Figure 167 2). The first is related to the canonical transient receptor potential (TRPC) proteins, 168 which are thought to be molecular entities of receptor-activated cation channels. We preferentially activated Ang II-stimulated Gq protein-dependent signaling, which is 185 required for vascular smooth muscle hypertrophy 57 . We also found that AT1R-P2Y6R It is hoped that researchers will quickly identify new drugs that can be used to treat 297 COVID-19 and deliver them to patients suffering from severe COVID-19 as soon as The authors declare no conflicts of interest. A Novel Coronavirus from Patients with Pneumonia 317 in China A novel coronavirus outbreak of global 319 health concern The proximal origin of 321 SARS-CoV-2 Angiotensin-converting enzyme 2 is a functional 323 receptor for the SARS coronavirus SARS-CoV-2 Cell Entry Depends on 325 ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Mechanisms of SARS-CoV-2 entry into cells Risk factors for severe and critically ill COVID-19 Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England Genomic Evidence of SARS-CoV-2 Reinfection Involving E484K Spike Mutation Detection of a SARS-CoV-2 variant of 344 concern in South Africa Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 346 pandemic Tracking cryptic SARS-CoV-2 lineages 348 detected in NYC wastewater Clinical course and outcomes of critically ill patients with 350 SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Pathological findings of COVID-19 associated with acute 353 respiratory distress syndrome Risk factors for severity and mortality in adult COVID-19 355 inpatients in Wuhan Clinical characteristics of COVID-19-infected cancer 34 Clinical trials on drug repositioning for COVID-19 treatment RNA-Dependent RNA Polymerase by Remdesivir Mechanism of action of T-705 against review Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug 416 Interactions with Cardioactive Medications. Cardiovascular drugs and therapy The FDA-approved drug 419 ivermectin inhibits the replication of SARS-CoV-2 in vitro Dexamethasone to combat cytokine storm in 421 COVID-19: Clinical trials and preliminary evidence Long-term cardiovascular outcomes of COVID-19 Multiorgan and Renal Tropism 425 of SARS-CoV-2 Much More Than Just a Receptor for SARS-COV-2 Soluble ACE2-mediated cell entry of SARS-CoV-2 429 via interaction with proteins related to the renin-angiotensin system Ibudilast attenuates Science signaling Redox-dependent internalization of the 446 purinergic P2Y(6) receptor limits colitis progression Hypoxia-induced interaction of filamin 448 with Drp1 causes mitochondrial hyperfission-associated myocardial senescence Depolysulfidation of Drp1 induced by 451 low-dose methylmercury exposure increases cardiac vulnerability to hemodynamic overload. 452 Science signaling Screened antipsychotic drugs inhibit SARS-CoV-2 binding 65 SARS-CoV-2 entry Inhibition of PIKfyve kinase prevents infection 467 by Zaire ebolavirus and SARS-CoV-2 Characterization of spike glycoprotein of SARS-CoV-2 on 470 virus entry and its immune cross-reactivity with SARS-CoV Cathepsin L-selective inhibitors: A potentially 472 promising treatment for COVID-19 patients Targeting TMPRSS2 and Cathepsin B/L 474 together may be synergistic against SARS-CoV-2 infection SARS-CoV-2-neutralising monoclonal 477 antibodies for treatment of COVID-19 Molnupiravir for Oral 479 Treatment of Covid-19 in Nonhospitalized Patients Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious 481 illness, company reports Effect of Vaccination 483 on Household Transmission of SARS-CoV-2 in England Initial report of decreased SARS-CoV-2 485 viral load after inoculation with the BNT162b2 vaccine Effectiveness of COVID-19 vaccines against 76 SARS-CoV-2 Omicron has extensive but incomplete 490 escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv Post-acute COVID-19 syndrome 306 We thank Katherine Thieltges from Liwen Bianji (Edanz) (www.liwenbianji.cn/) for